Tuberous Sclerosis Complex Management
Introduction to TSC Management
- The American College of Cardiology and other guideline societies recommend the use of mTOR inhibitors, such as everolimus, for the treatment of renal angiomyolipomas, subependymal giant cell astrocytomas (SEGA), and other TSC-associated tumors 1.
Treatment Approaches
- mTOR inhibitors are effective in reducing the size of angiomyolipomas and slowing disease progression 2, 3.
- Proteinuria may develop or worsen during mTOR inhibitor treatment, requiring regular monitoring 1.
Renal Management
- All TSC patients should undergo regular renal monitoring from the time of diagnosis, as cysts and angiomyolipomas can develop in the first months of life 4, 2, 1.
- Normal kidney imaging and GFR in young children do not guarantee the absence of future renal lesions 2, 1.
- Arterial embolization should be considered as the first-line approach for actively bleeding lesions 1.
- Preventive arterial embolization may be considered for asymptomatic angiomyolipomas larger than 4 cm, especially those with rich angiomyomatous content 1.
Blood Pressure and Kidney Function Monitoring
- All patients should undergo standardized office blood pressure measurements annually 1, 5.
- Ambulatory blood pressure monitoring should be performed in adults with blood pressure ≥120/70 mmHg 1.
- Annual kidney function and proteinuria assessment should be performed in adults and children with renal involvement 1, 5.
- ACE inhibitors or ARBs are recommended as first-line treatment for hypertension 1.
- SGLT2 inhibitors may be considered for patients with CKD progression, although evidence is limited in the TSC population 1.
Multidisciplinary Care Model
- All TSC patients should receive coordinated care from a multidisciplinary team, including neurology, nephrology, pulmonology, dermatology, and other specialties, to reduce mortality and morbidity 1, 5.
Kidney Disease Phenotypes and Frequencies
- TSC-associated kidney disease consists of three main phenotypes: angiomyolipomas (70-80%), cystic disease (approximately 50%), and renal cell carcinoma (3-5%) 2, 3, 5.
- These phenotypes are not mutually exclusive, and patients often have a combination of angiomyolipomas and cysts 2.
Anatomical and Functional Evaluation
- Anatomical evaluation, including imaging, should be performed to assess kidney involvement 2.
- Functional evaluation, including GFR and proteinuria assessment, should be performed to monitor kidney function 1, 5.
Neurological Management
- Epilepsy should be monitored and treated, as it is a leading cause of mortality in TSC patients 1, 5.
Genetic Evaluation and Family Screening
- Genetic screening should be discussed with family members 1.
- Family members with TSC clinical features should be screened for known pathogenic variants 1.
Post-Kidney Transplantation Management
- mTOR inhibitors may be considered as part of the immunosuppressive regimen in patients with TSC-associated kidney disease after kidney transplantation 1.